Sinovac Biotech Ltd., of Beijing, said the CFDA issued the new drug certificate and approved the production license for its enterovirus 71 (EV71) vaccine – the first innovative vaccine product developed and commercialized by the company. Sinovac said it expects to receive its GMP license shortly and plans to begin commercial production of the vaccine immediately afterward, with initial shipments expected four to five months following the start of production.